Antiandrogen with drawal syndrome;Das antiandrogen-entzugssyndrom

Urologe - Ausgabe A

Volumn 37, Issue 2, 1998, Pages 156-158

  Breul, J ^a   Paul, R ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antiandrogen withdrawal; Prostate cancer; Prostate specific antigen

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; CHLORMADINONE ACETATE; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN DERIVATIVE; MEGESTROL ACETATE; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER;

ARTICLE; HUMAN; MALE; ORCHIECTOMY; PROSTATE CANCER; WITHDRAWAL SYNDROME; BLOOD; DISEASE COURSE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATE TUMOR; REVIEW;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FLUTAMIDE; HUMANS; MALE; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SUBSTANCE WITHDRAWAL SYNDROME; TUMOR MARKERS, BIOLOGICAL;

EID: 0032018260     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001200050165     Document Type: Article

References (21)

1. Akakura K, Akimoto S, Ohki T, Shimazaki J (1995) Antiandrogen withdrawal syndrom in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology 45: 700-704
2. Belani CP, Pearl P, Whitley NO, Aisner J (1989) Tamoxifen withdrawal response. Arch Intern Med 149: 449-450
3. Bissada NK, Kaczmarek AT (1995) Complete remission of hormone refractory adenocarci-noma of the prostate in response to withdrawal of diethylstilbesrol. J Urol 153: 1944-1945
4. Breul J, Paul R (1997) Das Antiandrogenentzugsyndrom. Akt Urol 5: 267-270
5. Crawford ED, DeAntonio EP, Labrie F, Schröder FH, Geller J (1995) Endocrine therapy of prostate cancer: optimal form and appropriate timing. J Clin Endocrin Metab 80: 1062-1066
6. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radlmayr C, Eberle J, Bartsch G, Klocker H (1993) Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7: 1541-1550
7. Dawson NA, McLeod DG (1995) Dramatic prostate-specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrom. J Urol 153: 1946-1947
8. Dupont A, Gomez J, Cusan L, Koutsilieris M, Labrie F (1993) Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 150: 908-913
9. Figg WD, Sator O, Cooper MR, Thibault A, Bergan R, Dawson N, Reed E, Myers CE (1995) Prostate-specific antigen decline following the discontinuation of flutamide in patients with D 2 prostate cancer. Am J Med 98: 412-414
10. Gaddipati GP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancer. Cancer Res 54: 2862-2864
11. Huan SD, Gerridzen RG, Yan JC, Stewart DJ (1997) Antiandrogen withdrawal syndrom with nilutamide. Urology 49:632-634
12. Kelly WK, Scher HI (1993) Prostate-specific antigen decline after antiandrogen withdrawal. J Urol 149: 607-609
13. Newmark JR, Hardy EO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER (1992) Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 89: 6319-6323
14. Nieh PT (1995) Withdrawal phenomenon with the antiandrogen casodex. J Urol 153: 1070-1073
15. Sartor O, Cooper M, Weinberger M, Headlee D, Tomkins A, Thibault A, Myers CE (1994) Surprising activity of flutamid withdrawal when combined with aminoglutethimide, in the treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst 86: 222-227
16. Scher HI, Feng Zang Z, Cohen L, Kelly WK (1995) Hormonally relapsed prostatic cancer: lesson from the flutamide withdrawal syndrome. Adv Urol 8: 61-95
17. Scher HI, Feng Zhang Z, Naus D, Klein WK (1996) Hormone and antihormone withdrawal: implications for the managment of androgen independent prostate cancer. Urology 47 [Suppl 1 A]: 61-69
18. Small EJ, Carrol PR (1994) Prostate specific antigen decline after bicalutamid withdrawal: evidence for an antiandrogen withdrawal syndrom. Urology 43: 408-410
19. Small EJ, Schellhammer P, Venner P, Haas G, Nieh P Seabaugh DR, Patterson AL, Klein E, Wajsman Z, Furr B, Chen Y, Kennealey GT, Kolvenbag G (1996) A double blind assessment of antiandrogen withdrawal from Casodex or Eulexin therapy while continuing luteinizing hormone releasing hormone analogue therapy for patients with stage D 2 prostate cancer. Proc Am Soc Clin Oncol 15: 658
20. Velscholte J, Ris-Stalpers C, Kuipers GG, Jenster G, Berrevoets CA, Classen E, van Rooij HCJ, Trapman J, Brinkmann AO, Mulder JE (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affect binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173: 534-543
21. Wilding G, Cheng M, Gelmann EP (1989) Aberrant response in vitro of hormone responsive prostate cancer cells to antiandrogens. Prostate 14: 103-114